Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System

被引:0
|
作者
Jing Huang
Long Meng
Bing Yang
Shusen Sun
Zhigang Luo
Hong Chen
机构
[1] The First Affiliated Hospital of Chongqing Medical University,Department of Respiratory and Critical Care Medicine
[2] The First Affiliated Hospital of Chongqing Medical University,Department of Pharmacy
[3] Chongqing Medical University,Department of Nursing
[4] Western New England University,Department of Pharmacy Practice, College of Pharmacy and Health Sciences
[5] Xiangya Hospital Central South University,Department of Pharmacy
[6] Central South University,Institute for Rational and Safe Medication Practices, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital
[7] Department of Pharmacy,undefined
[8] Shihezi People’s Hospital,undefined
来源
Scientific Reports | / 10卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Adverse event reports submitted to the US Food and Drug Administration (FDA) were analyzed to map the safety profile of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). We conducted a disproportionality analysis of the adverse events (AEs) of EGFR-TKIs (gefitinib, erlotinib, afatinib, osimertinib) by data mining using the FDA adverse event reporting system (AERS) database, and by calculating the reporting odds ratios (ROR) with 95% confidence intervals. The FDA AERS database contained 27,123 EGFR-TKI-associated AERs within the reporting period from January 1, 2004 to March 31, 2018. Thirty-three preferred terms (PTs) were selected for analysis, and significant RORs were most commonly observed in the skin, nail, gastrointestinal tract, hepatic, eyes, and lungs. Unexpected adverse drug reactions were found in the “intestinal obstruction” and “hypokalaemia” in gefitinib and erlotinib, “hyponatraemia” in gefitinib, erlotinib and afatinib, “alopecia”in erlotinib, “hair growth abnormal” in afatinib, but not in “nausea” and “vomiting” listed on drug labels. The results of this study are consistent with clinical observation, suggesting the usefulness of pharmacovigilance research should be corroborated with the real-world FAERS data.
引用
收藏
相关论文
共 50 条
  • [21] Safety profile analysis of Sunitinib and Dasatinib protein kinase inhibitors using FDA adverse event reporting system (FAERS) database
    Alyami, Fatimah
    Guo, Jeff J.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 335 - 336
  • [22] Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system
    Yibei Zhao
    Huiming Jiang
    Lifen Xue
    Mi Zhou
    Xiaobing Zhao
    Fei Liu
    SongJiang Jiang
    Jing Huang
    Long Meng
    International Journal of Clinical Pharmacy, 2024, 46 : 480 - 487
  • [23] Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system
    Zhao, Yibei
    Jiang, Huiming
    Xue, Lifen
    Zhou, Mi
    Zhao, Xiaobing
    Liu, Fei
    Jiang, Songjiang
    Huang, Jing
    Meng, Long
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024, 46 (02) : 480 - 487
  • [24] The real-world safety profile of empagliflozin: a disproportionality analysis based on the FDA Adverse Event Reporting System (FAERS) database
    Hu, Huiping
    Liu, Maochang
    Fu, Zhiwen
    Li, Shijun
    Wang, Kaiping
    Huang, Zi
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [25] A disproportionality analysis of CDK4/6 inhibitors in the FDA Adverse Event Reporting System (FAERS)
    Peng, Yuan
    Zhou, Yuying
    Zhou, Xuanyi
    Jia, Xu
    Zhong, Yan
    EXPERT OPINION ON DRUG SAFETY, 2025, 24 (01) : 25 - 33
  • [26] Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system
    Cheng, Qian
    Shi, Xuan
    Zhao, Yazheng
    Zou, Shupeng
    Sun, Minghui
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (05) : 637 - 648
  • [27] Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
    Shu, Yamin
    Ding, Yufeng
    Liu, Yanxin
    Wu, Pan
    He, Xucheng
    Zhang, Qilin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [28] A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System
    Xu, Jiayan
    Wang, Ruo
    Shen, Kunwei
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2025, 16
  • [29] Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system
    Chang, En
    Shi, Yong-Fang
    Liu, Jin-Feng
    Wei, Wei
    EXPERT OPINION ON DRUG SAFETY, 2024, 23 (12) : 1545 - 1552
  • [30] A Disproportionality Analysis of Treprostinil Based on FDA Adverse Event Reporting System Database
    Li, Lingling
    Song, Weiqiang
    Jiao, Wanli
    ANNALS OF PHARMACOTHERAPY, 2024,